Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The study objective was to evaluate the safety and efficacy of a single 16, 16-dimethyl prostaglandin E2 (PGE2) vaginal suppository for achieving nonmechanical dilation when administered 12 hours prior to a 1st trimester suction curettage. 20 women between 7 and 12 weeks gestation who wanted an abortion volunteered to be the study subjects. 4 women were primigravidas and 16 were multiparous. All the women had normal medical histories and clinical examinations. Cervical dilatation, if any, was measured with Hegar dilators and recorded in millimeters. The serum concentration of prostaglandin reached its highest levels 4 hours following the insertion of the vaginal suppository. A higher level between 2 and 4 hours cannot be ruled out. Serum progesterone levels showed a slight decrease in 3 patients and no significant change in the other 4 patients. Cramping was noted in 17 of 20 patients. Its onset occurred between 1 hour and 8 hours post insertion. Vaginal bleeding occurred in 19 patients 1-12.5 hours. All patients were found to have a significant degree of cervical softening and cervical dilation when examined at 12 hours following the insertion of the suppository. 16 patients (80%) did not require any further medical dilation. The additional amount of cervical dilation for the 4 remaining patients ranged from 1 mm to 3 mm and was greatly facilitated by a softened cervix. 2 of these 4 women were primigravidas. 10 patients passed "tissue" per vagina during the observation period, prior to the termination procedure. Chorionic villi was confirmed by histologic examination in only 3 instances. The systemic absorption of the paracervical anesthetic was apparently increased since the initial group of patients complained of dizziness, numbness of tongue, and/or bitter taste in mouth. Study results indicate that a single 16, 16-dimethyl PGE2 vaginal suppository can "prime" the cervix so the further mechanical dilation was easily accomplished and in most cases (80%) was completely eliminated.
 ...
PMID:Intravaginal administration of 9-deoxo-9-methylene-16,16-dimethyl PGE2 for cervical dilation prior to suction curettage. 612 34

A randomized trial conducted in the US and Cuba assessed whether moistening misoprostol in advance of vaginal insertion enhances the efficacy of medical abortion after methotrexate administration. 240 abortion seekers from Pittsburgh, Pennsylvania (US), and Havana, Cuba, with pregnancies of 49 days' gestation or less were randomized either to dip the four 200-mcg misoprostol tablets in water before administration (group 1) or to insert the tablets dry (group 2). The misoprostol dose was repeated in 1-2 days if abortion did not occur. There were no statistically significant differences between groups 1 and 2 in the cumulative rate of abortion after the first misoprostol dose (73.0% vs. 71.3%), after the second misoprostol dose (84.1% vs. 81.1%), or by 35 days after methotrexate administration (95.2% vs. 91.8%). The proportion of women with a continuing pregnancy, defined as the presence of embryonic cardiac activity 2 weeks after methotrexate injection, was slightly but nonsignificantly higher in group 2 (5.7%) than in group 1 (2.4%). The immediate success rate in Pittsburgh was greater, although not significantly, for women who moistened the misoprostol (87% vs. 76%); in Havana, the opposite trend was observed (82% vs. 86%). Cramping began a mean of 2.8 hours after the first misoprostol administration in group 1 and a mean of 3.5 hours later in group 2. Women in group 1 had significantly more diarrhea (36% vs. 21%) and fever/chills (44% vs. 30%) than those in group 2, but rates of nausea, vomiting, dizziness, and headache did not differ. These findings suggest that moistening misoprostol before vaginal application does not significantly improve the efficacy of methotrexate abortion.
 ...
PMID:A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. 1034 81